Roth Capital Reiterates Neutral On Sunesis Following Data From Phase I/II AML/MDS Study
Roth Capital analyst Joseph Pantginis reiterated a Neutral rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) with a $2.30 price target, as the company presented data from its ongoing Phase I/II study of vosaroxin with decitabine in newly diagnosed elderly AML and MDS patients.
Pantginis noted, “With uncertainty looming overhead following VALOR data, we believe this study can help rebuild confidence and interest in vosaroxin and demonstrate a possible path forward with a potentially more responsive patient population. As was pointed out at the ASH oral presentation, the ORR is high and since this is a population that is not suited for chemotherapy, their treatment options are limited.”
“Therefore, we believe this is an appealing path forward for the drug and these data warrant further investigation in this patient population as they may respond better than the VALOR patient population.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -2.1% and a 47.4% success rate. Pantginis has a -75.6% average return when recommending SNSS, and is ranked #3054 out of 3401 analysts.